611 W. Union Street
Benson, AZ 85602
(520) 586-0800

Health Choice Integrated Care crisis Line

NurseWise 24-Hour Crisis Line


611 W. Union Street
Benson, AZ 85602
(520) 586-0800

NurseWise 24-Hr Crisis Line


powered by centersite dot net

Getting Started
Here are some forms to get started. These can be printed and brought with you so that you can pre-fill out some known info ahead of time. More...

Medical Disorders
Basic InformationLookupsLatest News
Excess Weight May Raise Rosacea RiskDecline in Antibiotic Use in Livestock Isn't Enough, Critics SayCould a Hot Cup of Tea Preserve Your Vision?Breathing Retraining Beneficial in Patients With AsthmaZika Babies Facing Increasing Health Problems With AgeHealth Tip: Dental Association Supports Fluoridated WaterAnother Legacy of Terror Attacks: MigrainesRain May Not Cause Achy Joints After AllDisrupted Sleep Linked to Increased Amyloid-β ProductionAtherosclerosis ID'd in Many Without CV Risk FactorsArtificial Intelligence Promising for CA, Retinopathy DiagnosesFirst Drug Approved for Rare Condition That Inflames Blood VesselsProtecting Your Health From Wildfire SmokeHealth Tip: Recognize Warning Signs of HypothermiaNew Hope for Kids With Multiple Food AllergiesFew Patients, Providers Discuss Costs of Glaucoma Medicationsβ-Cell Sensitivity to Glucose Impaired After Gastric BypassHow to Perk Up the Holidays for Hospital PatientsVigorous Exercise May Help Slow Parkinson's DiseaseIf Mom Has Rheumatoid Arthritis, Baby May Develop It, TooNew Gene Therapy May Be Cure for 'Bubble Boy' DiseaseAnother Gene Therapy Breakthrough Against HemophiliaPrenatal Sugar Intake May Increase Asthma Risk in OffspringObesity May Be Tied to Higher Rosacea Risk in WomenGot Scabies? Here's What to DoAre Women With Parkinson's at a Disadvantage?Bariatric Surgery Alters Liver Fatty Acid MetabolismORBIT Bleeding Risk Score Performs Best in A-FibHealth Tip: Prevent the Spread of NorovirusAre Good Kidneys Going to Waste?Metabolic Risk Factors Linked to Severe Liver DiseaseImpaired White Matter Integrity for Depression in Parkinson'sHave Eczema? No Need for Bleach Baths, Study SuggestsPowerful Clot-Busting Drugs Not Useful After Leg Blockages: StudyComing Soon: A Gel That Could Help Save Soldiers' EyesGene Therapy May Allow Hemophilia Patients to Go Without MedsThyroidectomy-Specific Quality Improvement Measures ID'dPatients OK With Fewer Opioids After Gallbladder SurgeryShhhh! Patients Are SleepingDiagnostic Mutations ID'd in Chronic Kidney Disease PatientsAntithrombotics Deemed Safe in Carpal Tunnel Release SurgeryLink Between Diabetes, Antibiotic Use Called Into QuestionHealth Tip: Diagnosing PneumoniaNoisy Commutes Could Cause Long-Lasting DamageThe Buzz on How Flies Spread DiseaseRisk of Surgical Complications Up for Overlapping Hip SurgeryOral Microbiome Composition Linked to Esophageal Cancer RiskSmartphone Pics Help Docs ID Kids' Skin ConditionEven Non-Heart Surgery May Harm Your HeartCan Scrotal Vein Condition Hike Heart Risks?
Questions and AnswersLinksBook Reviews
Related Topics

Men's Health
Women's Health

Zika Vaccine Works in Early Human Trial

HealthDay News
by -- Mary Elizabeth Dallas
Updated: Oct 5th 2017

new article illustration

THURSDAY, Oct. 5, 2017 (HealthDay News) -- An experimental vaccine for the Zika virus has shown signs of success in an early human trial.

The vaccine safely produced Zika-specific antibodies in 100 percent of the people involved in the study.

"Zika virus continues to be a threat to people living in the Americas and the Caribbean," said study author Dr. Pablo Tebas, a professor of infectious diseases at the University of Pennsylvania in Philadelphia.

"With these new results, we are one step closer to hopefully finding a way to prevent infection, which can cause serious birth defects and developmental delays in babies born to women who are infected with Zika," he said.

The synthetic DNA-based Zika vaccine is known as GLS-5700. Unlike some vaccines that use weakened or killed versions of a virus, the experimental Zika vaccine contains synthetic DNA instructions that enable the immune system to neutralize the virus. The vaccine was developed by Inovio Pharmaceuticals, GeneOne Life Science and The Wistar Institute.

"Synthetic DNA vaccines are an ideal approach for emerging infectious diseases like Zika," study co-author David Weiner said in a Wistar news release. He's director of the institute's Vaccine & Immunotherapy Center.

Weiner said this new generation of DNA vaccines has significant advantages. They can be designed and manufactured rapidly. They also appear to be highly predictable for the generation of immunity in humans.

Plus, these vaccines are more stable than most traditional vaccines, "making them exceptionally practical to distribute during outbreaks, especially in regions where resources are limited and we need to be able to respond quickly to curb an emerging epidemic," Weiner said.

The trial included 40 people. It was conducted in 2016 from August to September. The participants were divided into two groups that received two different doses of the vaccine when the study began.

The study volunteers received additional doses at four and 12 weeks. Each dosage was delivered with Cellectra, a device that produces small, electric currents that help the body produce an immune response to the vaccine.

Two weeks after receiving the final dose of the vaccine, all 40 of the people involved in the study developed Zika-specific antibodies, the study showed.

The researchers noted that 80 percent of the participants developed significant protection against the virus. None of the people had a negative reaction to the vaccine.

Blood collected from the participants was also able to protect mice with weakened immune systems from Zika after they were infected with the virus.

This suggests that the antibodies triggered by the vaccine can prevent infection in living organisms.

The vaccine will need to be tested in larger trials.

The findings were published Oct. 5 in the New England Journal of Medicine.

This group of researchers isn't the only one working on Zika protection. Researchers from the University of Miami Miller School of Medicine reported Wednesday that they've developed a "cocktail" containing three potent antibodies. This cocktail was able to completely prevent Zika infection in a group of four lab monkeys.

Even if successful in future research trials, it's still only a temporary measure. But it would provide immediate protection. And, that could potentially protect the fetuses of pregnant women living in or traveling to areas where Zika is endemic.

That study was published in the journal Science Translational Medicine.

More information

The U.S. Centers for Disease Control and Prevention provides more information on Zika virus.